|
A multifaceted approach is needed to resolve the myriad of challenges in developing oral formulations of poorly soluble drugs.
Jun 2, 2013
By:
Adeline Siew, PhD, Patricia Van Arnum
A multifaceted approach is needed to resolve the myriad of challenges in developing oral formulations of poorly soluble drugs.
|
May 29, 2013
By:
Adeline Siew, PhD
Amgen and Astellas have entered into a strategic alliance to provide new medicines for serious unmet medical needs of Japanese patients. The alliance leverages the complementary capabilities of both companies through an innovative business model that combines Amgen's pipeline candidates with Astellas' deep knowledge of Japanese patient and physician needs, long-term commercial and regulatory experience, and strong presence as a leading company in Japan.
|
May 22, 2013
By:
Adeline Siew, PhD
Novo A/S, the holding company of Denmark's Novo Nordisk, has acquired Xellia Pharmaceuticals and purchased all shares of the group for approximately US$ 700 million.
|
May 22, 2013
By:
Adeline Siew, PhD
Pfizer has discontinued a Phase III study of its investigational cancer drug, inotuzumab ozogamicin, in relapsed or refractory aggressive non-Hodgkin lymphoma (NHL) after it failed to show benefit in overall survival.
|
May 21, 2013
By:
Adeline Siew, PhD
AbbVie and Galapagos have extended their collaboration on the clinical development of GLPG0634 to include Crohn's disease.
|
May 20, 2013
By:
Adeline Siew, PhD
AstraZeneca announced that three of its cancer compounds—moxetumomab pasudotox, olaparib and selumetinib—will be moving forward to Phase III clinical development. Oncology is one of the company's core therapy areas and accelerating the development of a number of new molecular entities in its pipeline is a strategic priority.
|
May 13, 2013
By:
Adeline Siew, PhD
Amgen and Zhejiang Beta Pharma have signed an agreement to form a joint venture to commercialize Amgen's Vectibix (panitumumab) in the Chinese market. The aim is to quickly and efficiently deliver Vectibix to patients in China. Vectibix is a fully human anti-epidermal growth factor receptor (EGFR) antibody approved by FDA for the treatment of metastatic colorectal cancer.
|
May 13, 2013
By:
Adeline Siew, PhD
Eli Lilly reported that enzastaurin did not meet the primary endpoint in a Phase III study, which evaluated the agent as a monotherapy for the prevention of relapse in patients with diffuse large B-cell lymphoma (DLBCL).
|
May 10, 2013
By:
Adeline Siew, PhD
Takeda and US vaccines maker Inviragen jointly announced that they have entered into a definitive agreement for Takeda to acquire Inviragen for an upfront payment of US$35 million and future payments of up to US$215 million upon achievement of key commercial milestones, linked to the progress of clinical development.
|
|
